DUBLIN--(BUSINESS WIRE)--The "Drug
Analysis: ALKS 8700" drug pipelines has been added to ResearchAndMarkets.com's
offering.
ALKS 8700 is an oral monomethyl fumarate molecule
being developed for the treatment of relapsing multiple sclerosis.
Alkermes
designed this drug to have Tecfidera-like efficacy, but to also display
superior gastrointestinal tolerability. After being administered, ALKS
8700 rapidly metabolizes into monomethyl fumarate.
While the
actual mechanism of monomethyl fumarate is unknown, the molecule has
been shown to activate the nuclear factor (erythroid-derived 2)-like 2
pathway, which is involved in the cellular response to oxidative stress.
ALKS
8700 is currently in the middle of its pivotal Phase III clinical trial
program, with Alkermes planning to submit a 505(b)(2) New Drug
Application in 2018.
Key Topics Covered:
List
of Figures
Figure 1: ALKS 8700 for multiple sclerosis -
SWOT analysis
Figure 2: Drug assessment summary of ALKS 8700 for
multiple sclerosis
Figure 3: Drug assessment summary of ALKS 8700
for multiple sclerosis
Figure 4: ALKS 8700 sales for multiple
sclerosis across the US and five major EU markets, by country, 2016-25
List
of Tables
Table 1: ALKS 8700 drug profile
Table 2:
ALKS 8700 Phase III trials in multiple sclerosis
Table 3: ALKS 8700
sales for multiple sclerosis across the US and five major EU markets, by
country ($m), 2016-25
For more information about this drug
pipelines report visit https://www.researchandmarkets.com/research/x8xfvt/alks_8700_drug?w=4
ALKS 8700 Drug Analysis 2018: An Oral Monomethyl Fumarate Molecule Being Developed for the Treatment of Relapsing Multiple Sclerosis - ResearchAndMarkets.com
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs